| Literature DB >> 32382301 |
Yan-Gu Tao1,2, Xiu-Fang Huang1, Jun-Yan Wang1, Meng-Ru Kang2, Ling-Jun Wang3, Shao-Xiang Xian1.
Abstract
Heart failure (HF), a clinical syndrome with a high incidence due to various reasons, is the advanced stage of most cardiovascular diseases. Huangqi is an effective treatment for cardiovascular disease, which has multitarget, multipathway functions. Therefore, we used network pharmacology to explore the molecular mechanism of Huangqi in treating HF. In this study, 21 compounds of Huangqi, which involved 407 targets, were obtained and reconfirmed using TCMSP and PubChem databases. Moreover, we used Cytoscape 3.7.1 to construct compound-target network and screened the top 10 compounds. 378 targets related to HF were obtained from CTD and GeneCards databases and HF-target network was constructed by Cytoscape 3.7.1. The 46 overlapping targets of HF and Huangqi were gotten by Draw Venn Diagram. STRING database was used to set up a protein-protein interaction network, and MCODE module and the top 5 targets with the highest degree for overlapping targets were obtained. GO analysis performed by Metascape indicated that the overlapping targets were mainly enriched in blood vessel development, reactive oxygen species metabolic process, response to wounding, blood circulation, and so on. KEGG analysis analyzed by ClueGO revealed that overlapping targets were mainly enriched in AGE-RAGE signaling pathway in diabetic complications, IL-17 signaling pathway, HIF-1 signaling pathway, c-type lectin receptor signaling pathway, relaxin signaling pathway, and so on. Finally, molecular docking showed that top 10 compounds of Huangqi also had good binding activities to important targets compared with digoxin, which was carried out in CB-Dock molecular docking server. In conclusion, Huangqi has potential effect on regulating overlapping targets and GE-RAGE signaling pathway in diabetic complications, IL-17 signaling pathway, HIF-1 signaling pathway, and so on to be a latent multitarget, multipathway treatment for HF.Entities:
Year: 2020 PMID: 32382301 PMCID: PMC7195658 DOI: 10.1155/2020/6473745
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Detailed information of compounds from Huangqi.
| Number | Molecule ID/PubChem CID | Molecule name | Molecule weight | OB (%) | DL |
|---|---|---|---|---|---|
| 1 | MOL000211 | Mairin | 456.78 | 55.38 | 0.78 |
| 2 | MOL000239 | Jaranol | 314.31 | 50.83 | 0.29 |
| 3 | MOL000296 | Hederagenin | 414.79 | 36.91 | 0.75 |
| 4 | MOL000033 | (3S,8S,9S,10 R,13R,14S,17R)-10,13-Dimethyl-17-[(2R,5S)-5-propan-2-yloctan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol | 428.82 | 36.23 | 0.78 |
| 5 | MOL000354 | Isorhamnetin | 316.28 | 49.60 | 0.31 |
| 6 | MOL000371 | 3,9-di-O-methylnissolin | 314.36 | 53.74 | 0.48 |
| 7 | MOL000378 | 7-O-methylisomucronulatol | 316.38 | 74.69 | 0.30 |
| 8 | MOL000380 | (6aR,11aR)-9,10-dimethoxy-6a,11a-dihydro-6h-benzofurano [3,2-c] chromen-3-ol | 300.33 | 64.26 | 0.42 |
| 9 | MOL000387 | Bifendate | 418.38 | 31.10 | 0.67 |
| 10 | MOL000392 | Formononetin | 268.28 | 69.67 | 0.21 |
| 11 | MOL000398 | Isoflavanone | 316.33 | 109.99 | 0.30 |
| 12 | MOL000417 | Calycosin | 284.28 | 47.75 | 0.24 |
| 13 | MOL000422 | Kaempferol | 286.25 | 41.88 | 0.24 |
| 14 | MOL000433 | Antianemia factor | 441.45 | 68.96 | 0.71 |
| 15 | MOL000438 | (3R)-3-(2-Hydroxy-3,4-dimethoxyphenyl)chroman-7-ol | 302.35 | 67.67 | 0.26 |
| 16 | MOL000439 | Isomucronulatol-7,2′-di-O-glucosiole | 626.67 | 49.28 | 0.62 |
| 17 | MOL000442 | 1,7-Dihydroxy-3,9-dimethoxy pterocarpene | 314.31 | 39.05 | 0.48 |
| 18 | MOL000098 | Quercetin | 302.25 | 46.43 | 0.28 |
| 19 | MOL000409 | Astragaloside IV | 785.09 | 22.50 | 0.15 |
| 20 | 13943286 | Cycloastragenol | 490.71 | — | — |
| 21 | 2782115 | Astragalus polysaccharide | 254.69 | — | — |
Figure 1Compound-target network: the red rectangle node represents Huangqi. The green circle nodes represent compounds of Huangqi. The purple arrow nodes represent targets related to Huangqi.
Topological parameter of top 10 compounds in compound-target network.
| Category | ID | ASPL | BC | CC | Degree |
|---|---|---|---|---|---|
| Compound | MOL000098 | 1.86 | 0.73 | 0.54 | 145 |
| Compound | MOL000422 | 2.53 | 0.23 | 0.40 | 57 |
| Compound | MOL000378 | 2.65 | 0.11 | 0.38 | 39 |
| Compound | MOL000392 | 2.69 | 0.10 | 0.37 | 34 |
| Compound | MOL000354 | 2.71 | 0.09 | 0.37 | 31 |
| Compound | MOL000296 | 2.77 | 0.08 | 0.36 | 23 |
| Compound | MOL000371 | 2.77 | 0.05 | 0.36 | 22 |
| Compound | MOL000380 | 2.79 | 0.03 | 0.36 | 20 |
| Compound | MOL000417 | 2.80 | 0.02 | 0.36 | 19 |
| Compound | MOL000239 | 2.85 | 0.01 | 0.35 | 12 |
Topological parameter of top 10 targets in compound-target network.
| Category | ID | ASPL | BC | CC | Degree |
|---|---|---|---|---|---|
| Target | PTGS2 | 2.00 | 0.07 | 0.50 | 12 |
| Target | PTGS1 | 2.00 | 0.07 | 0.50 | 11 |
| Target | NCOA2 | 2.11 | 0.05 | 0.47 | 9 |
| Target | AR | 2.17 | 0.04 | 0.46 | 7 |
| Target | DPP4 | 2.17 | 0.04 | 0.46 | 7 |
| Target | PRSS1 | 3.15 | 0.01 | 0.32 | 7 |
| Target | RXRA | 2.40 | 0.03 | 0.42 | 7 |
| Target | CHRM1 | 3.06 | 0.01 | 0.33 | 6 |
| Target | ESR1 | 3.34 | 0.01 | 0.30 | 6 |
| Target | ACHE | 3.14 | 0.01 | 0.32 | 6 |
Figure 2Heart failure-target network: the red rectangle node represents heart failure. The purple arrow nodes represent targets related to heart failure.
Figure 3Targets' intersection of heart failure and Huangqi network. (a) The blue circle represents targets of Huangqi from TCMSP. The pink circle represents targets of heart failure from CTD. The green circle represents targets of heart failure from GeneCards. (b) Targets' intersection of heart failure and Huangqi network: the green oval nodes represent targets of targets intersection of heart failure and Huangqi.
Information from UniProt of targets' intersection of HF and Huangqi.
| Number | UniProt | Target | Number | UniProt | Target | Number | UniProt | Target |
|---|---|---|---|---|---|---|---|---|
| 1 | P47989 | XDH | 17 | P08709 | F7 | 33 | P35354 | PTGS2 |
| 2 | P18825 | ADRA2C | 18 | Q12809 | KCNH2 | 34 | Q96EB6 | SIRT1 |
| 3 | P04792 | HSPB1 | 19 | Q03135 | CAV1 | 35 | P01584 | IL1 |
| 4 | P09601 | HMOX1 | 20 | P37231 | PPARG | 36 | P23219 | PTGS1 |
| 5 | P35228 | NOS2 | 21 | P02741 | CRP | 37 | P13726 | F3 |
| 6 | P08254 | MMP3 | 22 | Q16665 | HIF1A | 38 | P07550 | ADRB2 |
| 7 | P17302 | GJA1 | 23 | P29474 | NOS3 | 39 | P15692 | VEGFA |
| 8 | P22301 | IL10 | 24 | Q16236 | NFE2L2 | 40 | P01137 | TGF |
| 9 | Q13085 | ACACA | 25 | P07204 | THBD | 41 | P49841 | GSK3B |
| 10 | P01344 | IGF2 | 26 | P05121 | SERPINE1 | 42 | P13500 | CCL2 |
| 11 | P02452 | COL1A1 | 27 | P04637 | TP53 | 43 | P03956 | MMP1 |
| 12 | P00750 | PLAT | 28 | P08588 | ADRB1 | 44 | P42224 | STAT1 |
| 13 | P48736 | PIK3CG | 29 | P01375 | TNF | 45 | P05231 | IL6 |
| 14 | P00441 | SOD1 | 30 | P04049 | RAF1 | 46 | Q14524 | SCN5A |
| 15 | P27169 | PON1 | 31 | P31749 | AKT1 | |||
| 16 | P01579 | IFNG | 32 | P10451 | SPP1 |
Figure 4PPI network of targets intersection of heart failure and Huangqi: the red circle nodes represent the top 5 targets from PPI network of intersection of heart failure and Huangqi. The yellow circle nodes represent the other 41 targets from PPI network of intersection of heart failure and Huangqi. A larger size of a node means a greater degree.
Figure 5MCODE module of targets' intersection of heart failure and Huangqi: the red polygon nodes represent important targets in the most significant MCODE module from PPI network.
Figure 6GO analysis of intersection of targets for heart failure and Huangqi. (a) The most 16 notable biological functions of targets intersection of heart failure and Huangqi. (b) A subset of enriched terms is selected and presented as a network map with terms having similarities >0.3 connected by edges. (c) Each of the nodes represents a rich term that is first colored by its cluster ID and then colored by its P value. The deeper the orange, the smaller the P value.
Figure 7KEGG pathways of targets intersection of heart failure and Huangqi: the circle nodes represent genes enriched in KEGG pathways. The polygon nodes represent KEGG pathways of intersection of heart failure and Huangqi with P value ≤0.05. A larger size of a pathway means a larger degree.
Topological parameter of targets intersection of HF and Huangqi in KEGG pathways.
| Category | Name | ASPL | BC | CC |
| Degree | Enriched genes |
|---|---|---|---|---|---|---|---|
| Signaling pathway | AGE-RAGE signaling pathway in diabetic complications | 2.09 | 0.04 | 0.48 | 4.93 × 10−15 | 14 | AKT1, CCL2, COL1A1, F3, IL1 |
| Signaling pathway | IL-17 signaling pathway | 2.20 | 0.01 | 0.45 | 2.04 × 10−9 | 19 | CCL2, GSK3B, IFNG, IL1 |
| Signaling pathway | HIF-1 signaling pathway | 2.21 | 0.01 | 0.45 | 3.91 × 10−9 | 9 | AKT1, HIF1A, HMOX1, IFNG, IL6, NOS2, NOS3, SERPINE1, VEGFA |
| Signaling pathway | C-type lectin receptor signaling pathway | 1.88 | 0.02 | 0.53 | 1.09 × 10−7 | 31 | AKT1, IL10, IL1 |
| Signaling pathway | Relaxin signaling pathway | 2.23 | 0.01 | 0.45 | 6.17 × 10−7 | 13 | AKT1, COL1A1, MMP1, NOS2, NOS3, RAF1, TGF |
Vina scores of compound-target docking.
| ID | IL-6 | AKT1 | VEGFA | NOS3 | IL-1 | RAF1 |
|---|---|---|---|---|---|---|
| Compound 2 | −6.3 | −5.8 | −7.7 | −8.5 | −6.2 | −8.3 |
| Compound 3 | −10.7 | −10 | −12.3 | −16.7 | −11.3 | −13.8 |
| Compound 5 | −6.4 | −5.9 | −7.9 | −9.5 | −7 | −9.1 |
| Compound 6 | −6.1 | −5.8 | −7.1 | −8.2 | −6 | −8 |
| Compound 7 | −5.5 | −5.7 | −7.4 | −8.3 | −6 | −8.1 |
| Compound 10 | −6.3 | −6 | −7 | −8.7 | −6.2 | −8.2 |
| Compound 12 | −6.4 | −5.9 | −7.5 | −8.9 | −6.5 | −8.3 |
| Compound 13 | −6.4 | −5.7 | −7.4 | −9.3 | −7.1 | −8.9 |
| Compound 18 | −6.5 | −5.9 | −7.4 | −9.6 | −7 | −9 |
| Digoxin | −7.7 | −8.7 | −10.4 | −11.5 | −9 | −8.5 |
Cavities' sizes of compound-target docking.
| ID | IL-6 | AKT1 | VEGFA | NOS3 | IL-1 | RAF1 |
|---|---|---|---|---|---|---|
| Compound 2 | 339 | 138 | 467 | 4965 | 123 | 1650 |
| Compound 3 | 339 | 134 | 467 | 4965 | 167 | 1650 |
| Compound 5 | 216 | 134 | 331 | 4965 | 194 | 1650 |
| Compound 6 | 339 | 134 | 467 | 4965 | 194 | 1650 |
| Compound 7 | 185 | 134 | 467 | 4965 | 167 | 1650 |
| Compound 10 | 185 | 134 | 467 | 4965 | 167 | 1650 |
| Compound 12 | 185 | 134 | 467 | 4965 | 123 | 1650 |
| Compound 13 | 216 | 134 | 467 | 4965 | 194 | 1650 |
| Compound 18 | 216 | 134 | 742 | 4965 | 194 | 1650 |
| Digoxin | 216 | 134 | 467 | 363 | 167 | 227 |
Figure 8Molecular docking between compounds of Huangqi, digoxin, and targets. (a) Compound 2, compound 3, compound 5, compound 6, compound 7, compound 10, compound 12, compound 13, and compound 18 dock with IL-6 and AKT1. (b) Compound 2, compound 3, compound 5, compound 6, compound 7, compound 10, compound 12, compound 13, and compound 18 dock with VEGFA and NOS3. (c) Compound 2, compound 3, compound 5, compound 6, compound 7, compound 10, compound 12, compound 13, and compound 18 dock with IL-1β and RAF1. (d) Digoxin dock with IL-6, AKT1, VEGFA, NOS3, IL-1β, and RAF1.